Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin added early to alteplase thrombolysis for acute ischemic stroke
ISRCTN87656744Phase 3Completed
- Sponsor
- Interregional Clinical Diagnostic Center
- Start
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ischemic stroke comparing Control: alteplase alone with Case: Cerebrolysin plus alteplase (2 arms). Primary endpoints: Hemorrhagic transformation rate and Symptomatic intracranial hemorrhage. Started Apr 2018; status: completed.
02
Drugs
cerebrolysintissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ISRCTN87656744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN87656744.